Progyny, Inc. (NASDAQ: PGNY) is a Healthcare company (Medical - Healthcare Plans) with a market capitalization of $2.7B. The Maz Rating grades it against the other companies in its sector.
Progyny, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $36.71, Progyny, Inc. trades at 31.8x trailing earnings, 2.0x sales and 6.7x book value, with an EV/EBITDA of 18.6. Over the last twelve months it generated about $1.3B of revenue and $85M of net income. It runs a gross margin of 24.9%, an operating margin of 9.4% and a net margin of 6.8%. It shows return on equity of 20.0%, return on invested capital of 19.9% and a free cash flow yield of 8.1%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 1.93. Over the past 52 weeks the share price ranged from $16.10 to $37.21, with a beta of 0.97.
Progyny, Inc. does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 15 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Progyny, Inc. (PGNY) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.93% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.93% / 33% · Receivables / Mkt Cap (36m) 11.4% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.93% / 33.33% · Receivables / Mkt Cap (24m) 11.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.14% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 34.2% / 33.33% · Receivables / Avg Assets (4Q) 35.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 28.9% / 33.33% · (Cash+Recv) / Total Assets 65.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Progyny, Inc. (PGNY) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Progyny, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Progyny, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.